The Impact of Olaparib Dose Reduction and Treatment Interruption on Treatment Outcome in Platinum-Sensitive Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Ann. Oncol 2022 Feb 24;[EPub Ahead of Print], KE Francis, SI Kim, M Friedlander, V Gebski, IR Coquard, A Clamp, RT Penson, A Oza, T Perri, T Huzarski, C Martin-Lorente, SC Cecere, N Colombo, B Ataseven, K Fujiwara, G Sonke, I Vergote, E Pujade-Lauraine, JW Kim, CK LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.